FXR signaling in metabolic disease

被引：171

作者：

Zhang, Yanqiao ^{[1
,2
]}

Edwards, Peter A. ^{[1
,2
,3
]}

机构：

[1] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA

来源：

FEBS LETTERS | 2008年 / 582卷 / 01期

关键词：

FXR; bile acid; lipid; glucose;

D O I：

10.1016/j.febslet.2007.11.015

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, has been shown to be important in controlling numerous metabolic pathways; these include roles in maintaining bile acid, lipid and glucose homeostasis, in preventing intestinal bacterial infection and gallstone formation and in modulating liver regeneration and tumorigenesis. The accumulating data suggest that FXR may be a pharmaceutical target for the treatment of certain metabolic diseases. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：10 / 18

页数：9

共 78 条

[1] Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice [J].

Alberti, S ;

Schuster, G ;

Parini, P ;

Feltkamp, D ;

Diczfalusy, U ;

Rudling, M ;

Angelin, B ;

Björkhem, I ;

Pettersson, S ;

Gustafsson, JÅ .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (05) :565-573

[2] Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1 [J].

Alvarez, L ;

Jara, P ;

Sánchez-Sabaté, E ;

Hierro, L ;

Larrauri, J ;

Díaz, MC ;

Camarena, C ;

De la Vega, A ;

Frauca, E ;

López-Collazo, E ;

Lapunzina, P .

HUMAN MOLECULAR GENETICS, 2004, 13 (20) :2451-2460

[3] CHENODEOXYCHOLIC ACID THERAPY FOR HYPERTRIGLYCERIDEMIA IN MEN [J].

BATESON, MC ;

MACLEAN, D ;

EVANS, JR ;

BOUCHIER, IAD .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 5 (03) :249-254

[4]

Berg Rodney D., 1995, Trends in Microbiology, V3, P149, DOI 10.1016/S0966-842X(00)88906-4

[5] Expression and activation of the farnesoid X receptor in the vasculature [J].

Bishop-Bailey, D ;

Walsh, DT ;

Warner, TD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (10) :3668-3673

[6] FXR: a target for cholestatic syndromes? [J].

Cai, Shi-Ying ;

Boyer, James L. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (03) :409-421

[7] Transient impairment of the adaptive response to fasting in FXR-deficient mice [J].

Cariou, B ;

van Harmelen, K ;

Duran-Sandoval, D ;

van Dijk, T ;

Grefhorst, A ;

Bouchaert, E ;

Fruchart, JC ;

Gonzalez, FJ ;

Kuipers, F ;

Staels, B .

FEBS LETTERS, 2005, 579 (19) :4076-4080

[8] The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice [J].

Cariou, B ;

van Harmelen, K ;

Duran-Sandoval, D ;

van Dijk, TH ;

Grefhorst, A ;

Abdelkarim, M ;

Caron, S ;

Torpier, G ;

Fruchart, JC ;

Gonzalez, FJ ;

Kuipers, F ;

Staels, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) :11039-11049

[9] Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity [J].

Chen, F ;

Ananthanarayanan, M ;

Emre, S ;

Neimark, E ;

Bull, LN ;

Knisely, AS ;

Strautnieks, SS ;

Thompson, RJ ;

Magid, MS ;

Gordon, R ;

Balasubramanian, N ;

Suchy, FJ ;

Shneider, BL .

GASTROENTEROLOGY, 2004, 126 (03) :756-764

[10] Identification of a hormonal basis for gallbladder filling [J].

Choi, Mihwa ;

Moschetta, Antonio ;

Bookout, Angie L. ;

Peng, Li ;

Umetani, Michihisa ;

Holmstrom, Sam R. ;

Suino-Powell, Kelly ;

Xu, H. Eric ;

Richardson, James A. ;

Gerard, Robert D. ;

Mangelsdorf, David J. ;

Kliewer, Steven A. .

NATURE MEDICINE, 2006, 12 (11) :1253-1255

← 1 2 3 4 5 6 7 8 →